AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$ISRG

Widman Fredrik sold $408K of ISRG

Widman Fredrik (VP Corporate Controller) sold 1,089 shares of INTUITIVE SURGICAL INC (ISRG) at $374.44 ($0.41M total) across 2 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Widman Fredrik
Published Sep 16, 2026, 5:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 5:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ISRG
Bearish
medium confidence
Mentioned
$ISRG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGBearishLow
01

Why it matters

A $408K insider sale is modest for a large‑cap like ISRG, but may influence short‑term sentiment.

02

Market read

Primary disclosure of an insider sale; limited trading impact but worth noting for short‑term positioning.

03

What to watch

Potential tax planning or diversification motives behind the 10b5‑1 execution.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑15

Background

Form 4 filings disclose insider transactions; traders watch for material sales.

Company-level read

Ticker impact

$ISRGBearishMedium confidence
Context

VP Corporate Controller Widman Fredrik sold 1,089 shares for $408K via a 10b5‑1 plan.

Expected impact

Potential short‑term downward pressure, likely limited.

Evidence & confidence

Sale size is modest relative to market cap; impact depends on market perception of insider intent.

Market effects

Sector

Minimal effect on the broader medical‑device sector.

Regional

Limited to U.S. investors tracking Intuitive Surgical.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a bearish signal.

Key entities

  • Company
    Intuitive Surgical Inc.

    Developer of the da Vinci surgical system.

  • Insider
    Widman Fredrik

    VP Corporate Controller, reported sale under 10b5‑1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ISRG insider trading history →

Related articles

SEP 15
$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

yahoo.com2 min
SEP 14
$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

prnewswire.com2 min
SEP 10
$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

yahoo.com3 min
SEP 9
$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3

theglobeandmail.com3 min